Moreover, rescue experiments using SC79, an AKT agonist,38 partially restored the proliferative and migratory abilities of HCC cells by silencing DCTN2, further supporting the involvement of the AKT pathway in DCTN2‐mediated tumour suppression. The gene discussed is AKT1; the disease is hepatocellular carcinoma.